Has CXCL13 an added value in diagnosis of neurosyphilis?

In patients with syphilis, central nervous system (CNS) involvement is often difficult to determine. In patients who also are infected with human immunodeficiency virus (HIV), this is even more challenging, as cerebrospinal fluid (CSF) pleocytosis can be attributed to HIV, syphilis, or both. Hence, this study investigated (i) CSF chemokine (C-X-C motif) ligand 13 (CXCL13) as a potential marker to diagnose neurosyphilis in HIV-infected individuals and (ii) the added value of CSF CXCL13 to conventional CSF biomarkers, such as the rapid plasma reagin test (RPR), in diagnosing neurosyphilis. We included 103 syphilis patients from two centers in The Netherlands: 47 non-HIV-infected patients and 56 HIV-infected patients. A positive CSF-RPR was regarded as the gold standard for neurosyphilis. CSF CXCL13 levels were significantly higher in neurosyphilis patients when neurosyphilis was diagnosed by CSF-RPR (P = 0.0002) than in the syphilis control group. The sensitivity and specificity of CSF CXCL13 (cutoff of 76.3 pg/ml) to diagnose neurosyphilis by using positive CSF-RPR as the gold standard were 50% and 90%, respectively. CSF CXCL13 had an added value to CSF-RPR positivity in 70% of HIV-positive patients and in 33% of HIV-negative patients. Our data show that CSF CXCL13 might be a potential additional marker in neurosyphilis when other markers are not conclusive. The added value of CSF CXCL13 measurement to the current neurosyphilis gold standard appears to benefit HIV-positive patients more than HIV-negative patients.

Predominant association of Raoultella bacteremia with diseases of the biliary tract.

A case series of 14 patients with Raoultella bacteremia was compared with 28 Klebsiella oxytoca and 28 Klebsiella pneumoniae bacteremia cases. Forty-three percent of Raoultella bacteremia cases were associated with biliary tract disease, compared to 32% and 22% of patients with K. oxytoca and K. pneumoniae bacteremia, respectively.

First report of a Wautersiella falsenii isolated from the urine of an infant with pyelonephritis.

Here, we report the first isolation of Wautersiella falsenii from the urine of an infant with a complicated urinary tract infection. W. falsenii was correctly identified by matrix-assisted laser desorption ionisation time of flight mass spectrometry. The identification was confirmed by 16S polymerase chain reaction. Susceptibility test results of this isolate are reported. Ciprofloxacin treatment resulted in clinical and microbiological improvement.

Clinical impact of preincubation of blood cultures at 37°C.

The effect of immediate incubation of blood cultures at 37°C on the turnaround time and the impact of Gram stain results on antimicrobial management were investigated. During a 6-month period, blood cultures collected at the emergency department outside laboratory operating hours were preincubated at 37°C until transportation to the laboratory. Upon the arrival of blood cultures at the laboratory, Gram stains and subcultures were made from all bottles prior to further incubation in the automated system (Bactec 9240). Data from 1 year earlier, when all blood cultures were stored at room temperature, were used for comparison. In the study period, 79 episodes of bacteremia were detected for 75 patients, compared to 70 episodes for 67 patients in the control period. Preincubation of blood cultures at 37°C resulted in a 15-h reduction in the median time to reporting of Gram stain results, from 34 to 19 h (P, <0.001). With preincubation, 3 episodes (4%) of bacteremia were not detected by the Bactec 9240 system. Based on the reporting of the Gram stain results, appropriate antimicrobial therapy was initiated for 12% of all patients with positive blood cultures, while for 24% the therapy was streamlined. Thus, immediate incubation of blood cultures reduced the time to reporting of Gram stain results. However, not all episodes of bacteremia were detected by the Bactec 9240 system after preincubation at 37°C. Blood culture results contributed importantly to appropriate antimicrobial management.

Appropriate and inappropriate implantable cardioverter defibrillator interventions during secondary prevention.

BACKGROUND: ICD therapy is established therapy for secondary prevention after aborted sudden death or ventricular tachycardia. Long-term data on the incidence of appropriate and inappropriate interventions are scarce. METHODS AND RESULTS: We retrospectively studied 391 patients with an ICD for secondary prophylaxis: 247 (63%) with ischaemic heart disease (IHD) and 144 without IHD (37%). Fifty-four patients were free from left ventricular structural disease. Mean follow-up was 30.8 months. Kaplan-Meier methodology was used for survival analysis. The use of beta-blockers was high and similar in both groups (85% IHD; 88% non-IHD; P = 0.36). The incidence of appropriate interventions was identical in IHD and non-IHD (42.7% and 47.8% at 4 y; HR 1.0, P = 0.99). There was a yearly rate of first intervention around 5% even in the fourth and fifth year after implantation. The incidence of inappropriate interventions was about half that of appropriate ICD interventions (21.4% at 4 y). It was higher in patients who also had received appropriate therapy (HR: 2.73 in the IHD group, 1.61 in the non-IHD group, P < 0.001 for both). Atrial fibrillation was the most common cause of inappropriate interventions in IHD, and sinus tachycardia in those without LV disease. The incidence of inappropriate interventions was not dependent on the type of ICD (VVI vs. DDD), in any group. CONCLUSIONS: Patients with an ICD for secondary prophylaxis have a high rate of appropriate interventions, and remain at risk for developing a first intervention several years after implantation. Inappropriate interventions constitute a significant burden. Taking preventive measures (AV nodal slowing drugs, device selection and programming, patient counseling regarding allowable physical activity) is required to optimize the quality-of-life adjusted life-saving potential of ICDs.